ObGyn Intel
ObGyn Intelligence
← All Tools
📋 MFM Subspecialist Level Only

Maternal-Fetal Medicine
100 Questions

High-complexity questions spanning the full scope of MFM subspecialty practice — calibrated for experienced subspecialists and MFM fellows. Each question opens Claude or ChatGPT with instructions to respond at the highest evidence level with primary citations.

Amos Grünebaum, MD · Professor of Obstetrics & Gynecology, Maternal-Fetal Medicine
🔓 Subspecialist use only. These questions and AI responses are calibrated for experienced MFM practitioners. The AI is instructed to cite 3–5 primary peer-reviewed references per response from AJOG, NEJM, Lancet, SMFM, or major MFM trial publications. Always verify citations independently.
1
Fetal Growth Restriction: Pathophysiology and Management
10 questions
1
What is the evidence distinguishing placental versus constitutional FGR using Doppler, biometry, and biomarkers?
2
What are the PORTO and TRUFFLE trial criteria for FGR surveillance and how do they inform delivery timing?
3
What is the evidence for the cerebroplacental ratio as a predictor of adverse perinatal outcome in late-onset FGR?
4
How does absent versus reversed end-diastolic flow in the umbilical artery change delivery decision-making by gestational age?
5
What is the role of ductus venosus Doppler in the terminal stages of fetal compromise and what does the a-wave predict?
6
What is the evidence for the ISUOG staging system for FGR and how does it compare to the Delphi consensus?
7
What is the pathophysiology of brain-sparing and at what point does it fail to protect the fetal brain?
8
What is the evidence on expectant management versus delivery for early-onset FGR between 26 and 32 weeks?
9
What biomarkers — sFlt-1, PlGF, PAPP-A — have the strongest predictive value for early-onset FGR?
10
What is the recurrence risk of FGR and what interventions have evidence for prevention in a subsequent pregnancy?
2
Preeclampsia: Prediction, Prevention, and Critical Management
10 questions
11
What is the first-trimester combined screening algorithm for preeclampsia and what are its detection rates?
12
What is the evidence for the sFlt-1:PlGF ratio in predicting preeclampsia onset within two weeks?
13
What is the ASPRE trial and how did it redefine low-dose aspirin dosing and timing for preeclampsia prevention?
14
What is the mechanism by which low-dose aspirin prevents early-onset preeclampsia?
15
What is the CHIPS trial and how did it define tight versus less-tight blood pressure control in pregnancy?
16
What is the evidence for magnesium sulfate versus phenytoin for seizure prophylaxis in severe preeclampsia?
17
What is the MAGPIE trial and what neonatal considerations arise from maternal magnesium therapy?
18
What antihypertensive achieves the fastest blood pressure control in acute severe hypertension and what is the evidence?
19
What is atypical preeclampsia and how does it challenge the diagnostic criteria?
20
What is the long-term cardiovascular risk stratification for women after preeclampsia and what follow-up is evidence-based?
3
Preterm Birth: Pathobiology, Prediction, and Intervention
10 questions
21
What is the evidence for cervical length measurement combined with fetal fibronectin in predicting spontaneous preterm birth?
22
What is the pathobiology of intrauterine infection-driven preterm birth and how does it inform antibiotic choice?
23
What is the evidence for vaginal progesterone versus 17-OHPC for preterm birth prevention in singleton pregnancies?
24
What did the PROLONG trial show about 17-OHPC and how does it conflict with the MFMU 2003 trial?
25
What is the evidence for cervical cerclage in women with prior preterm birth and a short cervix versus history alone?
26
What is the role of the arabin pessary in preterm birth prevention and what did the ProTWIN and PECEP trials show?
27
What is the evidence for tocolysis beyond 48 hours and which agents have the best short-term safety profiles?
28
What is the fetal inflammatory response syndrome and how does it affect neonatal outcomes independently of gestational age?
29
What is the evidence for antenatal magnesium sulfate for fetal neuroprotection and what are the dosing protocols?
30
What is the role of progestogen supplementation after a cervical cerclage in preventing recurrent preterm birth?
4
Placenta: Accreta Spectrum, Previa, and Abruption
10 questions
31
What is the evidence-based ultrasound and MRI criteria for diagnosing placenta accreta spectrum?
32
What is the sensitivity and specificity of color Doppler lacunae versus MRI for predicting surgical blood loss in PAS?
33
What is the optimal surgical approach for planned cesarean hysterectomy in placenta percreta?
34
What is the evidence for uterine artery embolization and balloon occlusion in reducing hemorrhage in PAS?
35
What is the cell salvage evidence in PAS and when is it contraindicated?
36
What is the clinical staging of placenta accreta spectrum according to FIGO and how does it guide multidisciplinary planning?
37
What are the evidence-based criteria for expectant management of PAS and what are its maternal and perinatal risks?
38
What is the pathophysiology of placental abruption and what biomarkers or clinical features predict severity?
39
What is the evidence for delivery timing in chronic abruption with fetal growth restriction?
40
What is a vasa previa type I versus type II and what are the evidence-based screening protocols for each?
5
Multiple Gestations: TTTS, sIUGR, and TAPS
10 questions
41
What is the Quintero staging system for TTTS and what are the limitations of its prognostic value?
42
What is the evidence for fetoscopic laser photocoagulation versus amnioreduction in stage II-IV TTTS?
43
What is the Solomon technique for laser photocoagulation and what does it reduce compared to selective laser?
44
What is selective fetal growth restriction in monochorionic twins and how is umbilical artery Doppler used for classification?
45
What is twin anemia polycythemia sequence and how is it diagnosed postnatally and prenatally?
46
What is the evidence for expectant management versus intervention in type II sIUGR in monochorionic twins?
47
What is the recurrence risk of TTTS after laser treatment and what surveillance protocol is recommended?
48
What is the evidence for selective feticide in discordant anomalies in monochorionic versus dichorionic twins?
49
What is the timing of delivery recommendation for uncomplicated MCDA versus DCDA twin pregnancies by evidence?
50
What is the evidence on neurological morbidity in the surviving co-twin after single fetal demise in monochorionic pregnancy?
6
Fetal Anemia, Hydrops, and Transfusion
10 questions
51
What is the evidence-based threshold for middle cerebral artery PSV as a trigger for fetal blood sampling and transfusion?
52
What is the hemolytic disease of the fetus and newborn pathophysiology for anti-Kell compared to anti-D?
53
What is the evidence for intrauterine transfusion technique via intrahepatic vein versus intracardiac approach in hydrops?
54
What is the optimal hematocrit target after intrauterine transfusion and how is the transfusion volume calculated?
55
What is the evidence for IUT frequency intervals and what hemoglobin decline rate should guide re-transfusion timing?
56
What is the pathophysiology of non-immune hydrops and what are the most common etiologies by gestational age?
57
What is the evidence for maternal IVIG in anti-D and anti-Kell alloimmunization to delay or reduce transfusion frequency?
58
What is mirror syndrome and what are the maternal manifestations in the setting of severe fetal hydrops?
59
What is the evidence on neurodevelopmental outcomes in fetuses requiring multiple intrauterine transfusions?
60
What is the current evidence on anti-D prophylaxis dosing in the first trimester versus standard third trimester regimens?
7
Congenital Anomalies and Fetal Intervention
10 questions
61
What is the evidence for fetal myelomeningocele repair: the MOMS trial outcomes and long-term follow-up data?
62
What are the current eligibility criteria for open fetal surgery for myelomeningocele repair and what are the maternal risks?
63
What is fetoscopic MMC repair and what are the procedural advantages and outcomes compared to open surgery?
64
What is the evidence for FETO in severe pulmonary hypoplasia due to congenital diaphragmatic hernia?
65
What is the lung-to-head ratio and observed-to-expected LHR and how do they predict CDH outcomes?
66
What is the evidence for thoracoamniotic shunting in large fetal hydrothorax and its effect on hydrops resolution?
67
What is the evidence for vesicoamniotic shunting in lower urinary tract obstruction and which fetuses benefit?
68
What is radiofrequency ablation versus bipolar cord coagulation for selective feticide in monochorionic twins with anomalies?
69
What is fetal cardiac intervention — balloon valvuloplasty for aortic stenosis — and what are the selection criteria and outcomes?
70
What is the evidence for ex utero intrapartum treatment for large fetal neck masses and airway obstruction?
8
Maternal Cardiac and Pulmonary Disease in Pregnancy
10 questions
71
What is the modified WHO classification for maternal cardiac risk and which conditions are class IV?
72
What is Eisenmenger syndrome and what is the maternal mortality risk in pregnancy?
73
What is the evidence for beta-blocker use in Marfan syndrome during pregnancy and what aortic diameter triggers delivery planning?
74
What is the peripartum cardiomyopathy diagnostic criteria and evidence for bromocriptine therapy?
75
What is the evidence for anticoagulation in mechanical heart valve replacement during pregnancy?
76
What is the evidence for heparin versus warfarin in the first trimester for mechanical valve thromboembolism prevention?
77
What is the management of acute pulmonary embolism in pregnancy and what is the evidence for thrombolysis?
78
What is pulmonary arterial hypertension in pregnancy and what targeted therapies have evidence for use?
79
What is the evidence for planned delivery timing and mode in women with significant structural heart disease?
80
What is the CARPREG II risk score and how does it predict adverse cardiac events in pregnant women with heart disease?
9
Thrombophilia, Antiphospholipid Syndrome, and Maternal Autoimmune Disease
10 questions
81
What is the revised Sapporo criteria for antiphospholipid syndrome and what defines triple positivity?
82
What is the evidence for heparin plus aspirin versus aspirin alone in obstetric APS with recurrent pregnancy loss?
83
What is the evidence for hydroxychloroquine in pregnant women with SLE and its effect on disease flares?
84
What is neonatal lupus and what anti-Ro/SSA titer predicts congenital heart block?
85
What is the evidence for serial fetal PR interval monitoring to detect early congenital heart block in anti-Ro positive women?
86
What is the evidence for IVIG and dexamethasone in preventing progression of first-degree to complete congenital heart block?
87
What is catastrophic antiphospholipid syndrome and what are its treatment options in pregnancy?
88
What is the evidence for inherited thrombophilia screening after recurrent pregnancy loss and which mutations are clinically actionable?
89
What is the evidence for thromboprophylaxis in pregnant women with heterozygous Factor V Leiden without prior VTE?
90
What is the optimal low-molecular-weight heparin regimen in pregnancy and how is anti-Xa monitoring used?
10
Fetal Neurology, Genetics, and Advanced Prenatal Diagnosis
10 questions
91
What is the evidence for chromosomal microarray versus standard karyotype in fetuses with ultrasound anomalies?
92
What is exome sequencing in prenatal diagnosis and what is the incremental yield over chromosomal microarray in anomalous fetuses?
93
What is the evidence and limitations of whole genome sequencing for prenatal diagnosis of fetal anomalies?
94
What is the classification of fetal ventriculomegaly and what additional workup is indicated at each severity threshold?
95
What is the evidence for fetal MRI in evaluating posterior fossa abnormalities diagnosed on ultrasound?
96
What is iso-intense signal on fetal brain MRI and what does it indicate about cortical maturation?
97
What is the pathophysiology and prognosis of fetal agenesis of the corpus callosum with and without associated anomalies?
98
What is the SMFM classification of fetal anomalies for counseling — isolated versus syndromic versus lethal — and how is it applied?
99
What is expanded carrier screening yield and how does residual risk change counseling after a positive carrier result?
100
What is the evidence for RNA sequencing and proteomics as emerging tools in prenatal diagnosis of fetal anomalies?